OCDX News and Press, Ortho Clinical Diagnostics plc From 09/09/21

RARITAN, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the world’s largest pure-play in vitro diagnostics companies, today announced the pricing of the previously announced underwritten secondary ...

RARITAN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the world’s largest pure-play in vitro diagnostics companies, today announced that one of its shareholders (the “Selling Shareholder&#...

RARITAN, N.J., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics (IVD) companies, today announced that members of its management team are scheduled to participate in two upcoming in...

The following slide deck was published by Ortho Clinical Diagnostics Holdings plc in conjunction with their 2021 Q2 earnings call. For further details see: Ortho Clinical Diagnostics Holdings plc 2021 Q2 - Results - Earnings Call Presentation

Ortho Clinical Diagnostics Holdings plc (OCDX) Q2 2021 Results Conference Call August 04, 2021 05:00 PM ET Company Participants Chris Smith - Chairman and CEO Joe Busky - CFO Mike Iskra - EVP, Commercial Excellence and Strategy Conference Call Participants Vijay Kumar - ISI Tycho Peterson - J...

Image source: The Motley Fool. Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) Q2 2021 Earnings Call Aug 04, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Ortho Clinical Diagnostics Holdings plc (OCDX) Q2 2...

Ortho Clinical Diagnostics Expands COVID-19 Test Offerings with Emergency Use Authorization (EUA) of Total Nucleocapsid Antibody Test Canada NewsWire -- Ortho's new VITROS ® Anti-SARS-CoV-2 Total N test detects the individual's immune response to the COVID-19 ...

Ortho Clinical Diagnostics (NASDAQ:OCDX): Q2 Non-GAAP EPS of $0.16 beats by $0.02; GAAP EPS of -$0.09 misses by $0.09. Revenue of $492.5M (+26.1% Y/Y) beats by $19.11M. Company raised 2021 guidance to 10% to 12% Core revenue growth in constant currency and adj. EBITDA growth to 15% to 17%; Co...

Strong Revenue Growth Drives Financial Results Company Raises Fiscal 2021 Guidance Across all Key Metrics RARITAN, N.J., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world's largest pure-play in-vitro diagnost...

ORTHO OPTIX™ Reader Completes Transfusion Medicine Portfolio, Now Available in Canada Canada NewsWire RARITAN, N.J. , July 26, 2021 /CNW/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, tod...